Assessing Toxicity following Cancer Treatment
Research type
Research Study
Full title
Analysing the Determinants of Severe Immune-related Adverse Events in Cancer
IRAS ID
319338
Contact name
Gary/G Middleton
Contact email
Sponsor organisation
Research Governance & Integrity
Duration of Study in the UK
10 years, 0 months, 2 days
Research summary
There are many modalities of treatment now available for patients with solid cancers. These include surgery, chemotherapy and immunotherapy. One of the most serious side effects from immunotherapy is autoimmune in nature, this is where the host's immune system starts to attack healthy tissues. We have already demonstrated, through work in lung cancer patients, that there are specific immune cell signatures that can be used to predict the occurrence of these adverse autoimmune events. These side effects pose a huge healthcare burden in terms of morbidity and mortality to patients as well as the financial implications. Hence, we wish the immune response in patients with all types of solid cancer through prospective collection of blood and other samples in order to better understand what drives these complications and how we can optimise patient treatment pathways.
REC name
East of England - Cambridge South Research Ethics Committee
REC reference
22/EE/0301
Date of REC Opinion
11 Jan 2023
REC opinion
Further Information Favourable Opinion